These strong associations suggest that EZH2 and CXCR4 overexpression promotes tumor progression and that EZH2 and CXCR4 could possibly be used as biomarkers for a more aggressive phenotype of gliomas. This evidence concerns the gene CXCR4 and central nervous system cancer.